Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
|Articles|October 1, 2001
Oncology NEWS International
- Oncology NEWS International Vol 10 No 10
- Volume 10
- Issue 10
Nine More States Offer Medicaid Coverage for Breast and Cervical Cancer
WASHINGTON-Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.
Advertisement
WASHINGTONHealth and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.
Alabama, Georgia, Iowa, Mississippi, Missouri, North Dakota, South Carolina, Virginia, and Washington join 19 previously approved states.
Articles in this issue
almost 25 years ago
High-Dose IL-2 Is Standard in Advanced Renal Cell Canceralmost 25 years ago
RIT Safe, Effective in Elderly and Poor-Prognosis Patientsabout 25 years ago
FDA Approves Xeloda/Taxotere Combination for Advanced Breast Cancerabout 25 years ago
ODAC Recommends Approval of Radiolabeled Zevalinabout 25 years ago
Proteomics Moves From the Laboratory to Clinical Researchabout 25 years ago
Radiotherapy Not Needed in Older Lumpectomy Patients With Early Cancerabout 25 years ago
Raltitrexed + Oxaliplatin for Advanced Colorectal Cancerabout 25 years ago
Mental Fatigue Worries Chemotherapy Patientsabout 25 years ago
Patients Urged to Work With Professionals Against Fatigueabout 25 years ago
NCI Director Resigns to Head New Scientific InstituteAdvertisement
Related to this article
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pirtobrutinib in Frontline CLL/SLL
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
4
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
5